Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc. (NASDAQ:TVTX), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission.

We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...

The move comes after a Filspari phase 3 trial in that indication failed on its primary endpoint of eGFR slope, a measurement of kidney disease progression. It also comes as findings from a ...

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...

The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of ...

Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to ...